Ken Griffin
TLIS

Ken Griffin’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Ken Griffin’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,200
Closed -$113K – 14996
2021
Q3 		$113K Buy
+1,200
New +$160K ﹤0.01% 12721

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ken Griffin's TLIS Position: Q1 2024 in Review

Ken Griffin sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2024, closing a stake of 10,024 shares — an estimated $74.7K sold.

Ken Griffin first reported a position in TLIS in Q3 2021 and held it in 6 quarters. The position peaked at $163K in Q3 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q1 2024.

  • Ken Griffin reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ken Griffin sold 10,024 Talis Biomedical Corporation Common Stock shares in Q1 2024, an estimated $74.7K.
  • Ken Griffin first reported a position in Talis Biomedical Corporation Common Stock in Q3 2021 and held it in 6 quarters.
  • Ken Griffin's Talis Biomedical Corporation Common Stock position peaked at $163K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.